Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

85.95 -1.44 (-1.65%)
Official Closing Price Updated: 4:10 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Why Glaukos Stock Is Tanking Today
Proposed rates from CMS for fiscal 2022 weren't what investors expected. 
Via The Motley Fool
Mid-Morning Market Update: Markets Open Higher; Citigroup Earnings Beat Expectations
Following the market opening Wednesday, the Dow traded up 0.26% to 34,979.05 while the NASDAQ rose 0.40% to 14,736.66. The S&P also rose, gaining 0.30% to 4,382.38. The U.S.... 
Via Benzinga
Topics Earnings Stocks
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021
Upgrades CL King upgraded the previous rating for Compass Minerals International Inc (NYSE: 
Via Benzinga
Glaukos's Earnings: A Preview
Glaukos (NYSE:GKOS) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's look at Glaukos's Q1 earnings report. Net Income, Earnings, And Earnings Per... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Qualigen Therapeutics (NASDAQ:QLGN) stock moved upwards by 8.98% to $1.94 during Wednesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
William Blair Downgrades Glaukos After Disappointing CMS Rate; Shares Drop
Centers for Medicare and Medicaid Services (CMS) issued its fiscal 2022 proposed physician fee schedule, which included two combined Category I cataract plus stent procedure... 
Via Benzinga
Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule
From Glaukos Corporation
Via Business Wire
Glaukos Stock Sees Its Relative Strength Rating Improve To Key Above-80 Level
Glaukos stock had its Relative Strength (RS) Rating upgraded from 78 to 81 Thursday. Is Glaukos on your watchlist? 
Via Investor's Business Daily
Why Glaukos's Stock is Up During Today's Session
Glaukos's Stock Price And Volume Action Glaukos (NYSE:GKOS) is curre... 
Via Benzinga
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR
From Glaukos Corporation
Via Business Wire
Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt
From Glaukos
Via Business Wire
Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference
From Glaukos Corporation
Via Business Wire
Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement
From Glaukos Corporation
Via Business Wire
Glaukos Corp (GKOS) Q1 2021 Earnings Call Transcript
GKOS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Glaukos Corporation Announces First Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Announces the Release of its 2020 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia
From Glaukos Corporation
Via Business Wire
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5
From Glaukos Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021
Upgrades According to Oppenheimer, the prior rating for Glaukos Corp (NYSE:GKOS) was changed from Perform to Outperform. Glaukos earned $0.02 in the fourth quarter,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.